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Abstract
We report herein two patients who presented with bilateral hydronephrosis attributed to lupus
cystitis with two totally different clinical consequences. Both had systemic lupus erythematosus
complicated with nephritis and nephrotic range of proteinuria. During the investigation of their
proteinuria, they were noted to have a dilated collecting system. The site of obstruction was localized
at the vesicoureteric obstruction by excretory urogram. The hydronephrosis resolved spontaneously
in one patient before the commencement of any medical therapy, whereas in the other patient,
there was no response to steroid therapy. Augmentation enterocystoplasty was thus performed.
Reversible hydronephrosis caused by vesicoureteric junction obstruction in patients with systemic
lupus erythematosus has been reported. Immune-mediated vasculitis involving the ureter and
bladder mucosa was the postulated pathogenic mechanism. The condition usually showed good
clinical response upon immunosuppressive therapy. We conclude that systemic lupus erythematosus-
associated interstitial cystitis can have a spectrum of different prognoses.
Key words: Bladder/pathology, Cystitis/complications, Immunosuppressive agents/therapeutic use, Lupus
erythematosus, Systemic/pathology
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C A S E
R E P O R T
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune
disease entity with multiorgan involvement. The
involvement of the genitourinary tract has been
traditionally represented by glomerulonephritis.
Extrarenal involvement of the genitourinary tract is not
common. Bladder involvement in patients with SLE may
have been underestimated based on autopsy studies (1).
Idiopathic interstitial cystitis (IC) is a condition
characterized by chronic inflammation of the bladder
wall. This affects essentially middle-aged women. The
patient usually presents with typical irritative symptoms
including suprapubic discomfort, dysuria, and urine
frequency (2). No infective organism can be isolated from
the urine.
Interstitial cystitis in patients with SLE has been reported.
Most of these were young Chinese women. Obstructive
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suppressive therapy. The bladder volume on follow-up
uroflowmetry study when the disease remained in
remission still showed a contracted bladder with a volume
of 200 mL. Thus, augmentation enterocystoplasty was
performed 2 years after her first presentation for
symptomatic relief. Her renal function remained normal
after the surgery with a serum creatinine of 59 µM (0.66
mg/dL) and a serum albumin of 37 g/L.
Case 2
A 51-year-old man, with previous good health, was
referred for bilateral asymmetrical polyarthralgia
associated with hotness and swelling of the involved
joints, mainly the small hand joints, wrists, knees, and
elbow joints for 1 year. There was no history of skin
rash or oral mucosal lesions. He also was noted to have
frothy urine. He was referred to us when he began to
experience a fever of about 38oC. Laboratory
investigations showed normochromic, normocytic
anemia of 10 g/dL, and thrombocytopenia of 91 x 109 /L.
The erythrocyte sedimentary rate was increased to 57
mm/hour. His renal chemistry was normal with a serum
creatinine of 92 µM (1.05 mg/dL) and blood urea
nitrogen of 5.5 mM (15.4 mg/dL). He passed 5 g of
proteinuria per day with a creatinine clearance of 110
mL/min. His serum albumin was 25 g/dL. Immunologic
studies revealed a positive antinuclear antibody (titer 1:
2560, homogenous pattern) and a weakly positive direct
Coomb’s test but a normal serum haptoglobulin level.
There was high level of anti-DNA (926 IU/mL) with
depressed C3 and C4 levels (0.25 and <0.1 g/L,
respectively; normal range, 0.69-1.35 and 0.12-0.36 g/L,
respectively). The activated partial thromboplastin time
and thrombin time were prolonged (51.9 and 16.2
seconds, respectively). Anticardiolipin immunoglobulin
(Ig) G was more than 80 GPL IU/mL. A Venereal Disease
Research Laboratories test was nonreactive. An
ultrasound showed bilateral hydronephrosis and
hydroureter. No renal stone or mass was noted. A rectal
examination did not reveal any enlargement of the
prostate and the serum prostate specific antigen level was
not increased.
The patient complained of frequency and dysuria at this
time. He was treated with empirical cefuroxime therapy
after urine was sent for a microbiological culture. Later,
the urine specimen was found to be sterile. An excretory
urogram showed bilateral hydronephrosis and
hydroureter down to the vesicoureteric junction with the
right side being more affected (Fig. 1). A cystoscopy
performed 5 days later, however, revealed essentially
normal findings. A cystoscopic biopsy was not
performed. A renal isotope scan (DTPA scan) taken on
the next day showed mildly impaired renal dynamic
uropathy (OU) may or may not be the feature. The
condition usually showed good clinical response to
immunosuppressive therapy and was reversible. We
report herein two patients who presented with bilateral
hydronephrosis attributed to lupus cystitis with two
totally different clinical consequences.
CASE REPORT
Case 1
A 39-year-old woman who was a known case of SLE
had interstitial lung disease and was under the care of
respiratory physicians. She was maintained on long-term
oral prednisolone at a dose of 10 mg daily. She was
referred to Queen Elizabeth Hospital because of
persistent fever. Subsequent investigations revealed
active lupus activity with antibody to double-strand DNA
(anti-DNA) of 117 IU/mL (normal range, <60 IU/mL).
Her serum C3 level was 0.83 g/L (normal range, 0.69-
1.35 g/L) at that time. She was also noted to have a recent
decrease in serum albumin level to 21g/L together with
5 g daily of proteinuria. Her liver and renal chemistries
were otherwise normal. An ultrasonogram of the urinary
system showed bilateral hydronephrosis and hydroureter.
At that time, she began to experience urine frequency
and fever. Empirical cefuroxime therapy was started after
the urine was sent for culture. The urine culture revealed
sterility with no mycobacterium. A urinalysis showed a
small amount of red cells (+) and proteinuria (3+). A
uroflowmetric study showed an unstable bladder with
diminished bladder capacity to only 174 mL. An
intravenous urogram confirmed the bi lateral
hydronephrosis and hydroureter, with the site of
obstruction being located at vesical-ureteric junctions.
The bladder was small and trabeculated. A cystoscopy
was thus performed, which showed trabeculated bladder
mucosa with bilateral edematous ureteric orifices. A
bladder biopsy revealed IC.
The dosage of prednisolone was increased in
consideration of her disease activity. A renal biopsy
showed diffuse proliferative glomerulonephritis with
early membranous changes (World Health Organization
class IV and V). The disease remained active despite
steroid therapy and thus cyclophosphamide was added
later. The disease then went into remission gradual with
improvement of the serum albumin level (31 g/L). The
anti-DNA decreased to 19 IU/mL after 6 months of
cyclophosphamide therapy. The cyclophosphamide was
later replaced with azathioprine together with a
maintenance dose of steroid.
However, the patient’s urine symptoms persisted despite
anticholinergic agents (oxybutynin) and immuno-
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perfusion and glomerular function, but drainage was not
obstructed. A renal biopsy was performed the next week
under ultrasound guidance after the disappearance of
dysuria. An ultrasound before the biopsy, however,
showed complete resolution of hydronephrosis and
hydroureter. This ultrasound was performed 2 weeks after
the previous one. A renal biopsy later confirmed focal
proliferative glomerulonephritis (World Health
Organization class III). The patient was then started on
steroid therapy (oral prednisolone 30 mg daily) to control
the nephrosis and thrombocytopenia. His platelet count
decreased to 49 x 109 /L before steroid therapy. Ankle
edema and proteinuria gradually improved and the latest
blood test showed that serum creatinine was 86 µM
(0.97 mg/dL) and serum albumin was 38 g/L with daily
proteinuria of 0.18 g and a creatinine clearance
of 85.9 mL/min. The platelet count increased to 150 x
109 /L.
DISCUSSION
We report two Chinese patients with OU associated with
SLE. The disease activity of Case 1 increased despite
maintenance steroid therapy and her OU was attributed
to IC. This failed to respond to more potent cytotoxic
agents and surgical intervention was required. The
obstruction in Case 2, however, went into remission even
before commencement of medical therapy.
Interstitial cystitis in a patient with SLE was first reported
by Shipton (3). Subsequently, many similar scattered
reports followed and the condition was termed as lupus
cystitis. Kataoka et al (4) was the first group to report a
case of OU with bilateral hydronephrosis attributed to
IC secondary to SLE. Kim et al (5) reviewed 19 cases of
SLE complicated with OU. Most (84%) of these were
Chinese women with a mean age of 32 years. Most of
these patients had IC with bilateral hydronephrosis on
radiologic imaging or ultrasonogram. No infective
organisms could be isolated from the urine, as in the two
cases reported here. On cystoscopy, the bladder was small
with pale or hyperemic mucosa. Sometimes ulcers and
stellate scars were present (6). As in Case 1, there was
often a striking reduction of bladder capacity (7), and
the mucosa typically bled when it was dilated during
cystoscopy (8). Bladder biopsy revealed submucosal
lesion with edema, hemorrhages, mononuclear cell
infiltrates, and fibrosis (9). An intravenous pyelogram
may show vesicoureteral reflux and bilateral
hydronephrosis with an inverse relation to bladder
capacity.
The presence of IC in SLE does not necessarily mean
the development of OU. Development of this
complication depends on the severity and chronicity of
inflammatory activity during the course of IC secondary
to SLE (5). However, the development of IC is usually
associated with the disease activity and the presence of
multisystem involvement. There is a strong association
between IC and gastrointestinal manifestation of SLE
(5). Gastrointestinal manifestations can range from trivial
abdominal pain, vomiting, and diarrhea to life-
threatening paralytic ileus and malabsorption. These are
termed as lupus enteropathy. The association of IC and
lupus enteropathy suggests that both complications share
similar pathogenic mechanisms, although the exact
relationship is yet to be defined.
The pathogenesis of IC in SLE is unknown. Various
mechanisms including infection (10), small vessel or
lymphatic blockage, transverse myelopathy (11), and
immunosuppressive drug toxicity (12) have been
suggested. The autoimmune mechanism is the most
widely accepted pathogenic mechanism of IC.
Deposition of denatured DNA, IgG, IgM, IgA, and C3
by immunofluorescent studies in the bladder was shown
in SLE patients with IC (8). Immune complex-mediated
vasculitis has been suggested (13). Unfortunately, the
Figure 1. The excretory urogram of Case 2 shows bilateral
hydronephrosis and hydroureter down to the vesicoureteric junction,
with the right side being more affected. Partial holding up of contrast
above both vesicoureteric junctions were demonstrated.
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results of immunofluorescence studies in the bladder
biopsies of these wo cases were not available.
The natural history of bladder involvement in SLE is
not known, and the role of specific therapy remains
undefined. Most patients in various series responded
rapidly to a high dose of corticosteroid therapy with
improvement in urinary symptoms and bladder capacity
(7). However, as mentioned above, because bladder
manifestations usually occur in patients with active lupus,
these manifestations together with other organ
involvement such as lupus enteropathy can sometimes
lead to mortality (14). The responsiveness of chronic IC
to steroids seems to be higher in lupus-associated IC
compared with idiopathic IC (9).
The clinical courses of the two cases in this report are
not typical. The lupus activity of Case 1 increased despite
maintenance steroid therapy. Her OU was attributed to
IC as confirmed by bladder biopsy. However, this
showed no response to heavy immunosuppressive
therapy despite quiescent disease activity. Subsequently,
surgery was needed to relieve her urine symptoms. Case
2, however, showed spontaneous resolution of his urine
symptoms together with urological obstruction even
before the commencement of medical therapy. We cannot
find a similar case throughout our literature review. The
site of his urological obstruction was located at the
vesicoureteric junction, probably at the ureteric orifice,
although a bladder biopsy was not performed. This
suggests that the manifestation of bladder involvement
in SLE is a spectrum, as enteropathy, with various
severities and prognoses rather than a single entity.
In summary, bladder complications in systemic lupus
are not common, but important. They range from
spontaneous resolution to persistence and may require
surgical intervention. Early recognition of bladder
involvement is important, because it may be a partially
reversible cause of renal failure in a patient with SLE. It
is also possible that early identification and treatment of
the inflammation phase may preserve bladder size and
function, thus decreasing morbidity of patients with
lupus.
REFERENCES
1. Alarcon-Segovia D, Abud-Mendoza C, Reyes-Gutierrez E, Iglesias-
Gamarra A, Diaz-Jouanen E. Involvement of the urinary bladder in
systemic lupus erythematosus. A pathologic study. J Rheumatol
1984;11:208-10.
2. Sotolongo JR Jr, Swerdlow F, Schiff HI, Schapira HE. Successful
treatment of lupus erythematosus cystitis with DMSO. Urology 1984;
23:125-7.
3. Shipton EA. Hunner ’s ulcer (chronic interstitial cystitis): a
manifestation of collagen disease. Br J Urol 1965;37:443-9.
4. Kataoka K, Fujioka H, Kitamula K, Kashiwai K, Yoshioka H, Fujita
S. Contracted bladder in a patient with systemic erythematosus:
report of a case. Acta Urol Jpn 1980;26:209-13.
5. Kim HJ, Park JY, Kim SM, Woo YN, Koh BH, Cho OK, Ko YH, Park
MH. Systemic lupus erythematosus with obstructive uropathy. Case
report and review. J Korean Med Sci 1995;10:462-9.
6. Oravisto KJ. Interstitial cystitis as an autoimmune disease. A review.
Eur Urol 1980;6:10-3.
7. Orth RW, Weisman MH, Cohen AH, Talner LB, Nachtsheim D,
Zvaifler NJ. Lupus cystitis: primary bladder manifestations of
systemic lupus erythematosus. Ann Intern Med 1983;98:323-6.
8. Boye E, Morse M, Huttner I, Erlanger BF, MacKinnon KJ, Klassen
J. Immune complex-mediated interstitial cystitis as a major
manifestation of systemic lupus erythematosus. Clin Immunol
Immunopathol 1979;13:67-76.
9. Gordon HL, Rossen RD, Hersh EM, Yium JJ. Immunologic aspects
of interstitial cystitis. J Urol 1973;109:228-33.
10.Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of
infection in systemic lupus erythematosus. Arthritis Rheum 1974;
17:1-10.
11. Andrianakos AA, Duffy J, Suzuki M, Sharp JT. Transverse
myelopathy in systemic lupus erythematosus. Report of three cases
and review of the literature. Ann Intern Med 1975;83:616-24.
12.Aptekar RG, Atkinson JP, Decker JL, Wolff SM, Chu EW. Bladder
toxicity with chronic cyclophosphamide therapy in nonmalignant
disease. Arthritis Rheum 1973;16:461-7.
13.de la Serna AR, Alarcon-Segovia D. Chronic interstitial cystitis as
an initial major manifestation of systemic lupus erythematosus. J
Rheumatol 1981;8:808-10.
14.Meulders Q, Michel C, Marteau P, Grange JD, Mougenot B, Ronco
P, Mignon F. Association of chronic interstitial cystitis, protein-losing
enteropathy and paralytic ileus with seronegative systemic lupus
erythematosus: case report and review of the literature. Clin Nephrol
1992;37:239-44.
